An Open Label Study of Levetiracetam in Japanese Pediatric Patients With Partial Seizures

Epilepsy Clinical Trial

Official title:

An Open Label, Single-Arm, Multi-Center Study on the Efficacy, Safety and Pharmacokinetics of Levetiracetam in Pediatric Patients (4 to 16 Years) With Partial Seizures Despite Treatment With 1 or 2 Anti-Epileptic Drugs

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01063764
• Other study ID #: N01223
• Secondary ID: 2014-004335-39
• Status: Completed
• Phase: Phase 3
• First received: February 1, 2010
• Last updated: February 16, 2015
• Start date: January 2010
• Est. completion date: October 2013

Study information

• Verified date: February 2015
• Source: UCB Pharma
• Contact: n/a
• Is FDA regulated: No
• Health authority: Japan: Ministry of Health, Labor and Welfare
• Study type: Interventional

Clinical Trial Summary

Objective of the First Period: To evaluate the efficacy of Levetiracetam dry syrup at doses up to a maximum of 60 mg/kg/day or 3000 mg/day used as an adjunctive therapy in Japanese pediatric patients (4 to 16 years) with uncontrolled partial seizures despite treatment with 1 or 2 anti-epileptic drug(s).

Description:

Objectives of the Second Period: To provide the Levetiracetam treatment to subjects who are judged by the investigators to benefit from the long-term treatment and who are willing to continuously receive this drug. To continuously evaluate the safety of the Levetiracetam long-term administration at doses ranging from 20 mg/kg/day or 1000 mg/day to 60 mg/kg/day or 3000 mg/day in subjects who completed the First Period of this study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 73
• Est. completion date: October 2013
• Est. primary completion date: April 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 4 Years to 16 Years

Eligibility

Inclusion Criteria:

• The patient has partial Epilepsy and the diagnosis must be confirmed in the last 6 months

• The patients must be on a stable 1 or 2 anti-epileptic drug(s) treatment during the 4 weeks prior to Baseline and must have at least 8 partial seizures during the 8-week prospective Baseline Period

• Patient at the age of 4 to 16 years, and at the body weight of 11 to 82 kg

Exclusion Criteria:

• The patient has a treatable seizure etiology

• The patient has Epilepsy secondary to a progressive cerebral disease or any other progressively neurodegenerative disease, including Rasmussen and Landau-Kleffner diseases

• The patient has a history of status Epilepticus during the 3 months prior to Visit 1

• The patient has a past and present history of pseudo seizures

• The patient has a current diagnosis of Lennox-Gastaut syndrome

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Epilepsy
• Partial Seizures
• Seizures

Intervention

Drug:
• Levetiracetam
First Period: Dry syrup 50 %, 20 mg/kg/day or 1000 mg/day, 40 mg/kg/day or 2000 mg/day, 60 mg/kg/day or 3000 mg/day, twice daily administration Per Os (PO) for 14 weeks. Second Period: Dry syrup 50 % or tablets (250 mg and 500 mg strengths), 20 to 60 mg/kg/day or 1000 to 3000 mg/day, twice daily administration Per Os (PO) until indication granted.

Locations

Country	Name	City	State
Japan	21	Chuo
Japan	12	Hakodate
Japan	22	Hamamatsu
Japan	28	Hiroshima
Japan	7	Izumi
Japan	9	Kobe
Japan	3	Kodaira
Japan	30	Koga
Japan	10	Koushi
Japan	31	Kurume
Japan	23	Kyoto
Japan	2	Nagaoka
Japan	5	Nagoya
Japan	6	Nagoya
Japan	8	Neyagawa
Japan	1	Niigata
Japan	27	Okayama
Japan	24	Osaka
Japan	25	Osaka
Japan	11	Sapporo
Japan	13	Sendai
Japan	4	Shizuoka
Japan	26	Takatsuki
Japan	16	Tokyo
Japan	17	Tokyo
Japan	15	Yachiyo
Japan	14	Yamagata
Japan	19	Yokohama
Japan	20	Yokohama

Sponsors (1)

Lead Sponsor	Collaborator
UCB Japan Co. Ltd.

Country where clinical trial is conducted

Japan, 

References & Publications (1)

Nakamura H, Osawa M, Yokoyama T, Yoshida K, Suzuki A. [Efficacy and safety of levetiracetam as adjunctive therapy in Japanese children with uncontrolled partial-onset seizures: multicenter and open-label study (N01223), short term evaluation]. Brain Nerve — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in Partial Seizure Frequency Per Week Over the 14-weeks Treatment Period	The change in partial seizure frequency from Baseline (B) over the Treatment Period (T) is given as a percentage reduction computed as: (B values- T values) / B values x 100.; Positive values in percent reduction mean that the value decreased from Baseline during the first 14-week Period.; Frequency per week of partial seizures = (Total number of partial seizures in a certain Period/number of observation days in the Period) x 7.; Partial seizures can be classified into: Simple partial seizures; Complex partial seizures; Partial seizures evolving to secondarily generalized seizures.	From Baseline (Week 0-8) to the 14-weeks Treatment Period (First Period: 4 weeks Up-titration (Week 8-12) and 10 weeks Evaluation (Week 12-22)); Week 0-22	No
Primary	Incidence of Treatment-Emergent Adverse Events (TEAEs) During the Second Period (up to Three Years Until the Time of Approval Granted)	An Adverse Event (AE) is any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product which does not necessarily have a causal relationship with the pharmaceutical product. Incidence of treatment-emergent AEs is reported by the percentage of subjects with at least one treatment-emergent AE.	During the second Period from Visit 8 (Week 22) to the end of the Follow-up Period (up to three years until the time of approval granted)	No
Secondary	Change From Baseline in Partial Seizure Frequency Per Week Over the 10-week Evaluation Period	The change in partial seizure frequency from Baseline (B) over the Evaluation Period (E) is given as a percentage reduction computed as: (B values- E values) / B values x 100. Positive values in percent reduction mean that the value decreased from Baseline to the 10-week Evaluation Period.; Frequency per week of partial seizures = (Total number of partial seizures in a certain Period/number of observation days in the Period) x 7.; Partial seizures can be classified into: Simple partial seizures; Complex partial seizures; Partial seizures evolving to secondarily generalized seizures.	From Baseline (Week 0-8) to the 10-weeks Evaluation Period (Part of the first Period: Week 12 to Week 22)	No
Secondary	Partial Seizure Frequency Per Week Over the 14-weeks Treatment Period	The seizure frequency per week was calculated as: Frequency per week of partial seizures = (Total number of partial seizures in the Treatment Period/number of days for observation in the Treatment Period) x 7. Partial seizures can be classified into one of the following three groups: Simple partial seizures; Complex partial seizures; Partial seizures evolving to secondarily generalized seizures.	14-weeks Treatment Period (First Period: 4 weeks Up-titration (Week 8-12) and 10 weeks Evaluation (Week 12-22))	No
Secondary	Partial Seizure Frequency Per Week Over the 10-weeks Evaluation Period	The seizure frequency per week was calculated as: Frequency per week of partial seizures = (Total number of partial seizures in the Evaluation Period/number of days for observation in the Evaluation Period) x 7. Partial seizures can be classified into one of the following three groups: Simple partial seizures; Complex partial seizures; Partial seizures evolving to secondarily generalized seizures.	10-weeks Evaluation Period (Part of the first Period: Week 12 to Week 22)	No
Secondary	Percentage of Partial Seizures 50 % Responders Over the 14-weeks Treatment Period	50 % responders are those subjects which have a 50 % or more reduction in the frequency of partial seizures from Baseline to the Treatment Period. The results show the percentage of participants that are 50 % responders.; Partial seizures can be classified into one of the following three groups: Simple partial seizures; Complex partial seizures; Partial seizures evolving to secondarily generalized seizures.	14-weeks Treatment Period (First Period: 4 weeks Up-titration (Week 8-12) and 10 weeks Evaluation (Week 12-22))	No
Secondary	Percentage of Partial Seizures 50 % Responders Over the 10-weeks Evaluation Period	50 % responders are those subjects which have a 50 % or more reduction in the frequency of partial seizures from Baseline to the Evaluation Period. The results show the percentage of participants that are 50 % responders.; Partial seizures can be classified into one of the following three groups: Simple partial seizures; Complex partial seizures; Partial seizures evolving to secondarily generalized seizures.	10-weeks Evaluation Period (Part of the first Period: Week 12 to Week 22)	No
Secondary	Number of Seizure-free Subjects Over the 14-weeks Treatment Period	Seizure-free means not having a seizure of type I (Partial seizure).; Partial seizures can be classified into one of the following three groups: Simple partial seizures; Complex partial seizures; Partial seizures evolving to secondarily generalized seizures.	14-weeks Treatment Period (First Period: 4 weeks Up-titration (Week 8-12) and 10 weeks Evaluation (Week 12-22))	No
Secondary	Number of Seizure-free Subjects Over the 10-weeks Evaluation Period	Seizure-free means not having a seizure of type I (Partial seizure).; Partial seizures can be classified into one of the following three groups: Simple partial seizures; Complex partial seizures; Partial seizures evolving to secondarily generalized seizures.	10-weeks Evaluation Period (Part of the first Period: Week 12 to Week 22)	No
Secondary	Incidence of Treatment-emergent Adverse Drug Reactions (ADRs) During the Second Period (up to Three Years Until the Time of Approval Granted)	An Adverse Drug Reaction (ADR) is an Adverse Event for which a causal relationship between the product and the occurrence is suspected. Incidence of ADRs is reported by the number of subjects with at least one ADR.	During the second Period from Visit 8 (Week 22) to the end of the Follow-up Period (up to three years until the time of approval granted)	No
Secondary	Change From Baseline in Partial Seizure Frequency Per Week for the Second Period (up to Three Years From Informed Consent Until the Time of Approval Granted)	The outcome was also calculated for each 3-month Period but here only the result for the total Second Evaluation Period (Second Period without following 6-weeks Withdrawal Period for withdrawers) is presented.; Change in partial seizure frequency from Baseline (B) over Second Evaluation Period (E) is given as a percentage reduction computed as: (B values- E values) / B values x 100. Positive values in percent reduction show a decrease from Baseline. Frequency per week of partial seizures = (Total number of partial seizures in a certain Period/number of observation days in the Period) x 7.	From Baseline (Week 0-8) until the time of approval granted (up to three years from date of informed consent (Week 0); without 6-weeks Withdrawal Period)	No

External Links

•   FDA Safety Alerts and Recalls
•   Keppra Tablets/Oral Solution